FIELD: medicine.
SUBSTANCE: invention refers to creation of peptides derived from area 32-51 of LALF proteins, deprived of LPS and heparin binding capability, and intensifying antineoplastic and immunomodulatory effect.
EFFECT: peptides and their combinations can be applied in cancer treatment, and also in a combination with the other standard therapies.
6 cl, 13 dwg, 1 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CDH3-PEPTIDE AND DRUG PREPARATION CONTAINING IT | 2008 |
|
RU2483078C2 |
| CDCA1 PEPTIDE AND PHARMACEUTICAL DRUG CONTAINING IT | 2008 |
|
RU2486195C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
| TEM8 PEPTIDES AND VACCINES CONTAINING THEM | 2008 |
|
RU2498993C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPY SCHEMES BASED ON VACCINES | 2013 |
|
RU2609651C2 |
| AGENTS AND METHODS BASED ON USING FIBRONECTIN OF DOMAIN EDA | 2006 |
|
RU2430738C2 |
| MYBL2 EPITOPE PEPTIDES AND VACCINES CONTAINING THEM | 2009 |
|
RU2496787C2 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
| ANTIBODY AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) AND APPLICATION THEREOF | 2015 |
|
RU2661678C1 |
| APPLICATION OF INHIBITING TGF-beta1 PEPTIDES FOR PREPARATION OF AGENT MODULATING IMMUNE RESPONSE | 2005 |
|
RU2420307C2 |
